Business Context and Reporting Period
This Form 8-K Current Report was filed by Alkermes Plc. on November 13, 2022. The filing addresses a legal development concerning the Company's intellectual property rights related to its product VIVITROL.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific legal event and does not contain financial performance data.
Material Changes
The primary material change reported is the rescheduling of a bench trial between Alkermes subsidiaries and Teva Pharmaceuticals USA, Inc. The trial, originally adjourned due to COVID-19, has been set to commence on February 16, 2023.
Outlook, Risks, and Contingencies
- Legal Contingency: The bench trial concerns the validity of U.S. Patent No. 7,919,499 (the "'499 Patent").
- Infringement Stipulation: Teva has stipulated that its abbreviated new drug application for a generic version of VIVITROL (naltrexone for extended-release injectable suspension) will infringe the asserted claims of the '499 Patent.
- Risk Factor: The outcome of the trial regarding the patent's validity remains a significant contingency for the Company's market exclusivity for VIVITROL.
Key Facts for Investor Verification
- The bench trial start date is now February 16, 2023.
- The dispute centers on the validity of U.S. Patent No. 7,919,499.
- Teva has admitted infringement of the patent claims but the patent's validity is the subject of the trial.
- The product at issue is VIVITROL (naltrexone for extended-release injectable suspension).